T(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1251-1257

  An, Gang ^a   Xu, Yan ^a   Shi, Lihui ^a   Zou, Dehui ^a   Deng, Shuhui ^a   Sui, Weiwei ^a   Xie, Zhenqing ^c   Hao, Mu ^a   Chang, Hong ^b   Qiu, Lugui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Chromosome aberration; Fluorescence in situ hybridization; Multiple myeloma; Prognosis; Survival

Indexed keywords

ACICLOVIR; BORTEZOMIB; CD20 ANTIGEN; CD56 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CLINICAL FEATURE; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 84883558588     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.020     Document Type: Article

References (27)

1. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
2. Munshi N.C., Anderson K.C., Bergsagel P.L., Shaughnessy J., Palumbo A., Durie B., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
3. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
4. Paiva B., Vidriales M-B., Montalbán M-A., Perez J.J., Gutierrez N.C., Rosiñol L., et al. Multiparameter flow cytometry (MFC) evaluation of plasma cell (PC) DNA ploidy status and proliferative rate in 595 multiple myeloma (MM) patients (pts) included in the Spanish GEM2000 and GEM2005<65years trials: clinical value and biological insights. Blood (ASH Annual Meeting Abstracts) 2011, 118:3938.
5. Avet-Loiseau H., Garand R., Lode L., Harousseau J.L., Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003, 101:1570-1571.
6. Fonseca R., Blood E.A., Oken M.M., Kyle R.A., Dewald G.W., Bailey R.J., et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
7. Garand R., Avet-Loiseau H., Accard F., Moreau P., Harousseau J.L. Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003, 17:2032-2035.
8. IMWG Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003, 121:749-757.
9. Fonseca R., Bergsagel P.L., Drach J., Shaughnessy J., Gutierrez N., Stewart K., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009.
10. Anderson K.C., Kyle R.A., Rajkumar S.V., Stewart A.K., Weber D., Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008, 22:231-239.
11. Fonseca R., Bailey R.J., Ahmann G.J., Rajkumar S.V., Hoyer J.D., Lust J.A., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002, 100:1417-1424.
12. Tiedemann R.E., Gonzalez-Paz N., Kyle R.A., Santana-Davila R., Price-Troska T., Van Wier S.A., et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008, 22:1044-1052.
13. Avet-Loiseau H., Daviet A., Brigaudeau C., Callet-Bauchu E., Terre C., Lafage-Pochitaloff M., et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001, 97:822-825.
14. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002, 99:2185-2191.
15. Chang H., Sloan S., Li D., Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet 2005, 156:150-153.
16. Albarracin F., Fonseca R. Plasma cell leukemia. Blood Rev 2011, 25:107-112.
17. Mateo G., Castellanos M., Rasillo A., Gutierrez N.C., Montalban M.A., Martin M.L., et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005, 11:3661-3667.
18. Robillard N., Avet-Loiseau H., Garand R., Moreau P., Pineau D., Rapp M.J., et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003, 102:1070-1071.
19. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
20. Hundemer M., Klein U., Hose D., Raab M.S., Cremer F.W., Jauch A., et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 2007, 40:1033-1037.
21. Pellat-Deceunynck C., Barille S., Jego G., Puthier D., Robillard N., Pineau D., et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998, 12:1977-1982.
22. Chang H., Bartlett E.S., Patterson B., Chen C.I., Yi Q.L. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol 2005, 129:539-541.
23. Blade J., Fernandez de Larrea C., Rosinol L., Cibeira M.T., Jimenez R., Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011, 29:3805-3812.
24. Avet-Loiseau H., Roussel M., Campion L., Leleu X., Marit G., Jardel H., et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia 2012, 26:158-159.
25. Chang H., Qi X.Y., Stewart A.K. t(11;14) does not predict long-term survival in myeloma. Leukemia 2005, 19:1078-1079.
26. Nair B., van Rhee F., Shaughnessy J.D., Anaissie E., Szymonifka J., Hoering A., et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
27. Walker B.A., Wardell C.P., Johnson D.C., Kaiser M.F., Begum D.B., Dahir N.B., et al. Characterization Of IgH breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pre-germinal center B cells. Blood 2013.